Combining biomarkers of clot resolution and alveolar basement membrane destruction predicts mortality in the ECLIPSE COPD cohort.

"Declaration of competing interest JMBS, SRR, LLL, MAK, TMJ and DJL are employed by Nordic Bioscience, Biomarkers and Research. MAK, TMJ and DJL hold stocks in Nordic Bioscience. Nordic Bioscience is a privately owned small-medium sized enterprise, partly focused on the development of biomarkers for connective tissue disorders. None of the authors from Nordic Bioscience received any kind of financial benefits or other bonuses for the work described in this manuscript. RTS and BEM are employees and shareholders of GSK. JV has received honoraria for presenting and advising from Astra Zeneca, Boehringer-Ingelheim, Chiesi, GlaxoSmithKline and Novartis, outside the submitted work."

"Funding GlaxoSmithKline (ECLIPSE; SCO104960, NCT00292552)."

"The study design of Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) (clinicaltrials.gov identifier NCT00292552; GSK study code SCO104960) has previously been described []. C4Ma3 [] and X-FIB [] plasma levels were assessed at the year 1 time point in a subpopulation of 982 COPD participants out of the total of 2164, as previously described [,]. Only patients with both C4Ma3 and X-FIB data were included in the current analyses. Data were dichotomized into high versus low based on the median. All-cause mortality at the year 3 time point was compared by Cox regression analysis and Kaplan-Meier survival curves for patients with no, one or two high biomarkers using the Statistical Software MedCalc version 14.8.1 (MedCalc Software bvba, Ostend, Belgium)."